Tesamorelin Canada: Visceral Fat Trial Evidence

Is tesamorelin a general “belly-fat” or weight-loss peptide? Its best-established clinical evidence concerns visceral adipose tissue in adults with HIV-associated abdominal fat accumulation. That specific population and endpoint matter: less visceral fat is not the same as general weight loss, and a research vial is not a prescription formulation.

This original FirstLabs editorial review was updated November 3, 2026. It is educational information, not medical advice, a dosing guide or a recommendation for personal use. FirstLabs catalogue materials are for laboratory research only, not human or veterinary use.

What is tesamorelin?

Tesamorelin is a stabilized analogue of growth hormone-releasing hormone (GHRH). It acts on the pituitary GHRH receptor and influences endogenous growth hormone and IGF-I signalling. That mechanism differs from incretin receptor agonists such as tirzepatide.

Mechanism alone does not establish clinical benefit. “Visceral adipose tissue” means fat within the abdominal cavity; subcutaneous abdominal fat sits beneath the skin. Trials measuring one compartment should not be described as proving removal of all abdominal fat.

What the human trials actually measured

2007 randomized trial: 412 adults, 26 weeks

The placebo-controlled trial enrolled 412 adults with HIV-associated abdominal fat accumulation; 86% were men. At 26 weeks, the tesamorelin group had a 15.2% decrease in CT-measured visceral adipose tissue, compared with a 5.0% increase with placebo. These are changes in a defined tissue compartment—not percentages of body-weight loss.

Pooled phase 3 analysis: 806 participants

The 2010 pooled analysis of two trials reported a visceral-fat change of −24 cm² with tesamorelin versus +2 cm² with placebo at week 26, with a reported treatment effect of −15.4%. Abdominal subcutaneous fat changed little. This makes “15% total fat loss” an inaccurate summary.

Triglyceride and other surrogate-marker improvements do not by themselves establish fewer cardiovascular events. The study populations were not representative samples of everyone with obesity, and their results cannot be applied to unrelated research products.

Durability and comparison limits

Extension studies found that continued treatment generally maintained visceral-fat reductions, while switching to placebo lost the effect. Continued-treatment and withdrawal data are useful, but extensions with switching and attrition are not equivalent to long-term placebo-controlled cardiovascular-outcomes trials.

The U.S. Egrifta SV prescribing information explicitly states that the product is not indicated for weight-loss management and that long-term cardiovascular safety has not been established. It would be misleading to compare its visceral-fat percentage directly with a tirzepatide or retatrutide body-weight percentage.

Claims about stacking peptides, universal body recomposition or cosmetic abdominal-fat reduction go beyond these trials. This review does not recommend combinations or personal-use protocols.

Safety is part of the evidence

The Egrifta SV label describes elevated IGF-I, fluid retention, glucose intolerance or diabetes risk, hypersensitivity and malignancy-related precautions. Fluid-retention effects can include swelling, joint discomfort and carpal-tunnel symptoms. These are documented risks and precautions, not a claim that every trial participant experienced them.

A hormone-signalling mechanism is not evidence of “natural” or risk-free treatment. Clinical supervision and manufacturing controls in a trial cannot be reproduced by a seller's purity statement. A research COA does not establish medical suitability.

Tesamorelin in Canada: past authorization versus current status

Health Canada's decision history documents a previous authorization for the prescription product Egrifta. However, the Drug Product Database record reviewed for this article lists that Egrifta record as Cancelled Pre Market, with a status date of July 13, 2023. Past authorization should not be described as proof of a currently marketed Canadian product.

U.S. approval, a historical Canadian decision or publication of a trial does not authorize FirstLabs tesamorelin research vials. Research materials do not inherit a prescription brand's formulation, manufacturing controls or drug authorization. Consult the current official product record for status changes, not a seller's headline.

Tesamorelin research: frequently asked questions

Did the trial show 15.2% body-weight loss?

No. It measured change in CT-assessed visceral adipose tissue in a specific HIV-associated population.

Is tesamorelin the same kind of compound as tirzepatide?

No. Tesamorelin is a GHRH analogue; tirzepatide acts at GIP and GLP-1 receptors. Their endpoints and populations cannot be ranked by comparing unrelated percentages.

Is a research vial equivalent to Egrifta?

No. A shared molecule name does not establish equivalent formulation, sterility, quality controls or authorization.

Laboratory documentation is a separate question

Evidence about tesamorelin in a clinical study does not establish that a FirstLabs vial is equivalent to the studied formulation. A certificate of analysis describes the submitted sample, not medical suitability or regulatory authorization. HPLC purity does not by itself establish quantity, sterility, endotoxin control or a match to current stock.

For laboratory records, verify exact identity and labelled size, analytical methods, measured quantity, sample identifiers and any available lot-to-stock documentation. A laboratory task ID is not automatically a manufacturing lot. Keep missing reports and adverse results visible rather than borrowing evidence from another size.

The Tesamorelin 10mg research catalogue entry describes a laboratory quantity, not a clinical dose. For a separate receptor comparison, see the existing Ipamorelin guide. Further Tesamorelin reviews: liver-fat trials, cognition trial and comparison with sermorelin, CJC-1295 and ipamorelin. The cover is an illustrative anatomy-and-laboratory scene, not a FirstLabs facility or an actual trial scan.

Read our COA verification checklist, published laboratory reports and Canadian regulation overview for these distinctions.

Primary sources and editorial scope

FirstLabs is a research-material supplier with a commercial interest in the compounds discussed, not a licensed pharmacy or an independent medical authority. Results belong to their original study populations, formulations and endpoints. No personal outcome, treatment protocol or authorization of catalogue products is implied.

Tesamorelin Research in Canada: Visceral Fat Evidence and Limits